share_log

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $205 Price Target

Benzinga ·  Nov 7 19:12  · Ratings

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $205 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment